TERESA TINCOPA: Open Payments
NPI 1609853233 · WHITTIER, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$627 in 30 payments from 11 companies in 2025. Trend: 2023 $476 · 2024 $466 · 2025 $627
Food & beverage: $627
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $147 |
| Lilly USA, LLC | 6 | $145 |
| AstraZeneca Pharmaceuticals LP | 4 | $77 |
| E.R. Squibb & Sons, L.L.C. | 3 | $49 |
| GlaxoSmithKline, LLC. | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Astellas Pharma US Inc | 1 | $30 |
| Mannkind Corporation | 1 | $30 |
| PFIZER INC. | 1 | $22 |
| Almatica Pharma LLC | 1 | $21 |
Products named: MOUNJARO, Ozempic, AIRSUPRA, Wegovy, COBENFY, TRELEGY ELLIPTA, GVOKE HYPOPEN, Veozah.
Industry payments across CA — which companies pay providers there.
